|
gptkb:2-Acetoxybenzoic_acid
|
gptkb:anticoagulant
|
|
gptkb:C11_207
|
gptkb:Hallucinogen
|
|
gptkb:YFL-221
|
gptkb:arylcyclohexylamine
|
|
gptkb:ST-18
|
gptkb:recreational_drug
|
|
gptkb:ST-18
|
gptkb:phenethylamine_derivative
|
|
gptkb:Polychlorinated_dibenzofurans
|
Group 2B carcinogen (IARC)
|
|
gptkb:2BH
|
gptkb:amphetamine
|
|
gptkb:OKB-276
|
gptkb:amphetamine_derivative
|
|
gptkb:ST-18
|
gptkb:substance_abuse
|
|
gptkb:2BH
|
psychedelic
|
|
gptkb:benzene_hexachloride
|
gptkb:persistent_organic_pollutant
|
|
gptkb:affine_type_A
|
gptkb:Kac–Moody_algebra
|
|
gptkb:Ro_11-1163
|
gptkb:tryptamine_derivative
|
|
gptkb:Vitamin_A_deficiency
|
public health problem by WHO
|
|
gptkb:2-Acetoxybenzoic_acid
|
nonsteroidal anti-inflammatory drug (NSAID)
|
|
gptkb:KP115
|
gptkb:opioid
|
|
gptkb:CHEMBL2219413
|
gptkb:small_molecule
|
|
gptkb:NMRA-140
|
gptkb:amphetamine_derivative
|
|
gptkb:lanatoside_C
|
cardenolide
|
|
gptkb:Asbestos_Exposure
|
Group 1 Carcinogen
|